Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
MWN-AI** Summary
Propanc Biopharma, Inc., a biopharmaceutical company focused on developing innovative treatments for chronic diseases, particularly pancreatic ductal adenocarcinoma (PDAC), recently announced significant findings regarding their lead product candidate, PRP, which contains bovine-derived proenzymes. Published in the peer-reviewed journal Scientific Reports, the study explores the effects of these proenzymes on cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) of PDAC.
The research highlights the dense fibrotic tissue prevalent in PDAC, which is essential in tumor growth and metastasis. CAFs play a pivotal role in tumor advancement by interacting with tumor cells, suggesting that targeting these stromal components could improve patient outcomes. PRP has demonstrated multifaceted effects on both CAFs and tumor cells, positioning it as a promising adjunct therapy. Dr. Belén Toledo, a co-lead researcher, emphasized the potential of PRP to disrupt key tumor-stroma interactions, offering a new approach to treating this aggressive form of cancer, which is projected to become a leading cause of cancer-related deaths by 2030 due to its late-stage diagnosis and limited treatment options.
Propanc's CEO, James Nathanielsz, expressed the company's commitment to advancing PRP through clinical trials, with a Phase 1b study planned for Q3 2026 targeting advanced cancer patients with solid tumors, including PDAC. The company anticipates that this pivotal study will inform the dosing for subsequent Phase 2 trials. This research publication marks a milestone in Propanc's development journey, with a focus on improving survival rates for patients diagnosed with PDAC, often characterized by a dismal prognosis. Propanc continues to position itself at the forefront of cancer therapeutics, seeking to change the landscape of treatment options available to patients facing this formidable disease.
MWN-AI** Analysis
Propanc Biopharma (Nasdaq: PPCB) recently made headlines with its research on proenzymes and their effects on pancreatic ductal adenocarcinoma (PDAC) fibroblasts, published in the peer-reviewed journal Scientific Reports. This breakthrough positions Propanc as a pivotal player in the biopharmaceutical market, especially concerning therapeutic strategies for cancer, which remains one of the leading global health challenges.
The study highlights how the company’s lead product candidate, PRP (pancreatic proenzymes), could disrupt the tumor microenvironment (TME) that significantly influences cancer progression. Notably, therapy targeting cancer-associated fibroblasts (CAFs) may lead to improved outcomes for patients with PDAC, an aggressive cancer characterized by late diagnoses and poor prognoses. The potential transition of PRP into clinical trials represents a strategic leap in combating a disease projected to become the second leading cause of cancer-related deaths by 2030.
Investors should view this development as a critical turning point. As Propanc prepares for its Phase 1b study set for Q3 2026, the clinical validation of PRP could unlock substantial market opportunities. The increasing focus on innovative therapeutic avenues in oncology positions the company favorably within a sector driven by unmet medical needs and high growth potential.
Market sentiments may fluctuate based on ongoing research results and regulatory navigations. Therefore, investors must weigh the inherent risks associated with biotechnology investments, especially those tied to clinical trial outcomes. For those willing to embrace this risk, Propanc’s strategic focus on disrupting CAF interactions could yield promising returns as it pursues advancements in cancer treatment.
Overall, monitoring Propanc’s progress in upcoming clinical trials and scientific disclosures will be essential for assessing investment viability in this promising biopharma landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced that the Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer reviewed journal, Scientific Reports, regarding the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. From the publishers of Nature, Scientific Reports is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences. The article is entitled, “Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts,” and available online. The tumor microenvironment (TME) plays a pivotal role in tumor initiation, progression, and the form of pre-metastatic niches. PDAC is characterized by a dense fibrotic stroma containing a significant enriched population of cancer-associated fibroblasts (CAFs). The interplay between CAFs and tumor cells is crucial in driving tumor advancement and metastasis, underscoring the potential benefits of novel therapeutic strategies targeting stromal cells to improve patient survival. PRP, consisting of two bovine derived pancreatic proenzymes, trypsinogen and chymotrypsinogen, have shown efficacy in cancer treatment. The findings demonstrate PRP exerts multifaceted effects. Results underscore the candidacy of PRP as a potential disruptor of the TME.
Future clinical investigation is planned to validate the translational potential of PRP as an adjunct therapy for PDAC patients who no longer respond to standard treatment regimen. Despite recent advancements in clinical management, PDAC remains one of the most aggressive and deadliest forms of cancer, projected to become the second leading cause of cancer-related deaths by 2030. PDAC is characterized by its late-stage diagnosis, limited treatment options, and poor prognosis.
“Our findings demonstrate that PRP exerts multifaceted effects specifically over the CAFs population and tumor cells. All together, these results highlight PRP as a promising adjunct therapeutic candidate capable of disrupting key interactions within the PDAC TME,” said Dr. Belén Toledo, PhD, joint lead researcher from the University of Jaén.
“After several years of research pioneered with our scientific researchers, we find ourselves publishing compelling scientific evidence that PRP has the potential to dramatically alter the way we perceive poor patients diagnosed with this killer disease,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We plan to undertake our Phase 1b study in advanced cancer patients suffering from solid tumors in Q3, 2026, and further announcements are anticipated. This pivotal study will determine our target dose for Phase 2 studies in which PDAC is one of our target therapeutic indications. We look forward to advancing PRP into the clinic as soon as possible to help PDAC patients with such a poor survival prognosis.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ**
How does Propanc Biopharma Inc PPCB plan to leverage its recent findings on proenzymes and pancreatic ductal adenocarcinoma to enhance patient outcomes and investor confidence in their upcoming clinical trials?
With the potential of PRP as a disruptor of the TME in PDAC, what strategies does Propanc Biopharma Inc PPCB have in place to attract partnerships and funding for its Phase 1b study set for Q3, 2026?
Given the aggressive nature of pancreatic ductal adenocarcinoma and its poor prognosis, how does Propanc Biopharma Inc PPCB differentiate its approach in targeting cancer stem cells from existing treatment options in the market?
What key milestones does Propanc Biopharma Inc PPCB anticipate achieving in the next year that will bolster its research credibility and prepare it for Phase 2 studies following the Phase 1b trial for advanced cancer patients?
**MWN-AI FAQ is based on asking OpenAI questions about Propanc Biopharma Inc (OTC: PPCB).
NASDAQ: PPCB
PPCB Trading
61.54% G/L:
$2.87 Last:
496,164 Volume:
$4 Open:
